Making a Lung Replacement

Making a Lung Replacement by the NIH

Hot on the heels of progress toward a liver transplant substitute, researchers have made transplantable lung grafts for rats. The accomplishment could pave the way for the development of an engineered human lung.

Blood vessels are preserved in the decellularized lung matrix. Image courtesy of Petersen et al., Science.

Lungs have a limited ability to regenerate. The primary therapy for severely damaged lungs is currently lung transplantation—surgery to remove the lung and replace it with a healthy lung from a deceased donor. However, lung transplants are limited by the small number of donor organs available—not much more than 1,000 per year.

To be successful, an artificial lung would need to retain the complex branching geometry of the lung’s airways. It would also require a large network of small blood vessels to transport oxygen and nutrients throughout the structure. Decellularization—the process of removing cells from a structure but leaving a scaffold with the architecture of the original tissue—has shown some success in other organs, including heart and liver. A team of researchers led by Dr. Laura Niklason of Yale University set out to build on this recent progress and develop a similar approach for lungs. Their work was supported by NIH’s National Heart, Lung and Blood Institute (NHLBI) and National Institute of General Medical Sciences (NIGMS).

The researchers harvested lungs from adult rats. Treating the lungs with a mild detergent solution for 2 to 3 hours removed the cells but left the lung architecture intact, as reported in the early online edition of Science on June 24, 2010. A careful analysis showed that a matrix of proteins remained behind to hold the lung’s shape.

To see if they could repopulate the matrix with cells and engineer a functional lung, the researchers injected endothelial cells into the blood vessels and epithelial cells into airways. They kept the matrix for up to 8 days in a novel bioreactor that was designed to mimic the pressure changes and ventilation a lung would experience. The researchers found that the cells reseeded the surfaces of the matrix in their appropriate locations. This finding suggests that the decellularized matrix maintains cues for the cells to attach and thrive.

The researchers tested the engineered lungs in rats for short time intervals (45-120 min) and found that the lungs inflated with air, with only some modest bleeding into airways. Most importantly, the lungs successfully exchanged oxygen and carbon dioxide like natural lungs.

To see whether their method might apply to human tissues, the researchers got human lung segments from a tissue bank. They were able to decellularize the tissues while preserving their architecture. They then reseeded the matrices with epithelial and endothelial cells and found that they adhered at their appropriate locations. This result supports the idea that the approach holds promise for human lung tissue.

“We succeeded in engineering an implantable lung in our rat model that could efficiently exchange oxygen and carbon dioxide, and could oxygenate hemoglobin in the blood. This is an early step in the regeneration of entire lungs for larger animals and, eventually, for humans,” says Niklason. She notes that years of research with adult stem cells will likely be needed to develop ways to repopulate lung matrices and produce fully functional lungs for people.

—by Harrison Wein, Ph.D.
Related Links:

* Lung Transplant:
http://www.nhlbi.nih.gov/health/dci/Diseases/lungtxp/lungtxp_whatis.html

Asthma Continues to be a Serious Public Health Problem

Asthma continues to be a serious public health problem. According to the Centers for Disease Control and Prevention

• About 23 million people, including almost 7 million children, have asthma.
* Asthma prevalence is higher among families with lower incomes.
• 12 million people report having an asthma attack in the past year.
• Asthma accounts for nearly 17 million physician office and hospital visits, 4 and nearly 2 million emergency department visits each year.
• African Americans continue to have higher rates of asthma emergency department visits, hospitalizations, and deaths than do Caucasians:
* The rate of emergency department visits is 350% higher.
* The hospitalization rate is 240% higher.
* The asthma death rate is 200% higher.
• Approximately 2 million Hispanics in the U.S. have asthma and Puerto Ricans are disproportionately impacted:
• The rate of asthma among Puerto Ricans is 125% higher than non-Hispanic white people and 80% higher than non-Hispanic black people.
• The prevalence of asthma attacks is highest among Puerto Ricans.

Asthma in Children:

• Asthma is one of the most common serious chronic diseases of childhood.
• Asthma is the third-ranking cause of hospitalization among children under 15.
• Asthma in children is the cause of seven million physician visits and nearly 200,000 hospitalizations.
• An average of one out of every 10 school-aged child has asthma.
• 13 million school days are missed each year due to asthma.

The Cost of Asthma:

• Annual expenditures for health and lost productivity due to asthma are estimated at over $20 billion, according to the National Heart, Lung, and Blood Institute.

Asthma and the Environment

Research by EPA and others has shown that:

• Dust mites, molds, cockroaches, pet dander, and secondhand smoke trigger asthma
attacks.
• Exposure to secondhand smoke can cause asthma in pre-school aged children.
• Exposure to dust mites can cause asthma.
• Ozone and particle pollution can cause asthma attacks.
* When ozone levels are high, more people with asthma have attacks that require adoctor’s attention.
* Ozone makes people more sensitive to asthma triggers such as pet dander, pollen, dust mites, and mold.

Asthma and Sleep Apnea

Asthma and Obstructive Sleep Apnea

According to research conducted by the National Institute of Health (NIH), mounting evidence implicates OSAS as a risk factor for asthma exacerbations, thereby linking these 2 major epidemics.

OBJECTIVE: To review the concept of a possible link between asthma and obstructive sleep apnea syndrome (OSAS) and the impact on asthma symptoms of treatment of OSAS with continuous positive airway pressure (CPAP) in patients with both conditions. DATA SOURCES: The Ovid, MEDLINE, and PubMed databases from 1950 to the present were searched for relevant articles regarding a possible relationship between asthma and OSAS and the effectiveness of CPAP in treating OSAS. STUDY

SELECTION: Articles describing pathophysiologic conditions occurring in OSAS that may be linked to asthma pathogenesis were used for this review. RESULTS: The data suggest that OSAS is an independent risk factor for asthma exacerbations. CPAP has been shown in prospective clinical studies to have a positive impact on asthma outcome in patients with concomitant OSAS. Ameliorative mechanisms of treatment with CPAP include mechanical and neuromechanical effects, gastroesophageal acid reflux suppression, local and systemic anti-inflammatory effects (including suppression of increased serum levels of inflammatory cytokines, chemokines, and vascular endothelial growth factor), cardiac function improvements, leptin level suppression, weight reduction, and sleep restoration.

CONCLUSIONS: Asthma and OSAS are increasingly troublesome public health issues. Mounting evidence implicates OSAS as a risk factor for asthma exacerbations, thereby linking these 2 major epidemics. We describe potential mechanisms whereby CPAP, the first line of therapy for OSAS, might modify airway smooth muscle function and asthma control in patients with both disorders. Despite the ever-increasing population of patients with both disorders, large, prospective, randomized controlled studies are necessary to more fully evaluate CPAP and asthma outcomes.

PLEASE NOTE: The information provided above is offered to you as a public service and not intended to replace your relationship with your physician. Please seek medical attention with any and all of your questions regarding your health.

Asthma Study Announced

Asthma and Flu Study Announced

Boston.com is reporting that researchers from Boston University are embarking on a national study of women who take medications or get vaccinated while they are pregnant, starting with flu and asthma treatments because they are widely taken and a common cause of concern.

BU’s Slone Epidemiology Center will compare women whose babies have major birth defects to mothers of normal babies, assessing their exposure to asthma medications, seasonal and H1N1 vaccine, and antiviral drugs such as Tamiflu. Based on information obtained from hospitals and birth registries, the researchers will interview mothers by telephone in Massachusetts, Philadelphia, San Diego, and New York state.

In another arm of the study, the Organization of Teratology Information Specialists will enroll pregnant women who use these medications or vaccines and compare them to pregnant women who don’t, following both groups after the babies are born.

“Our hope is to offer reassurance that a previously neglected area is going to receive some attention,” Slone director Dr. Allen Mitchell said in an interview.

Asthma drugs are the most commonly prescribed medications for pregnant women, he said, and health officials have noted pregnant women’s concerns about flu vaccine and medications.

“It’s not as though there’s good evidence that any of these agents are causing major problems,” Mitchell said. “Rather, there isn’t much data in the first place and some of the little data there are, are conflicting. Our hope is a large, rigorous study will be able to provide some credible answers.”

The study is funded by two federal bodies. The Agency for Healthcare Research and Quality is giving $2.5 million over five years and the Biomedical Advanced Research and Development Authority is spending $7.5 million for two years. Both grants are renewable. The effort, called the Vaccines and Medications in Pregnancy Surveillance System, or VAMPSS, is coordinated by the American Academy of Allergy, Asthma, and Immunology.

While the initial focus will be on flu and asthma, the surveillance system could be adapted to study other products pregnant women take in order to fill gaps in medical evidence, Mitchell said. “Postmarketing studies of drugs in pregnancy have been extremely haphazard.”